In a report released on June 25, from UBS maintained a Buy rating on CanSino Biologics, Inc. Class H, with a price target of HK$52.40. The comp...
CanSino Biologics, Inc. Class H has an analyst consensus of Moderate Buy, with a price target consensus of HK$52.40.
Based on CanSino Biologics, Inc. Class H’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of HK$188.56 million and a GAAP net loss of HK$40.06 million. In comparison, last year the company earned a revenue of HK$137.16 million and had a GAAP net loss of HK$11.55 million
In a report released on June 17, from UBS maintained a Buy rating on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H, with a…
In a report released yesterday, from UBS maintained a Buy rating on Weibo Corp Class A, with a price target of HK$85.80.Memorial…
Citi analyst maintained a Buy rating on Giant Biogene Holding Co. Ltd. on June 17 and set a price target of HK$37.00. The…
In a report released on May 27, from Citi maintained a Buy rating on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H, with a…
In a report released on May 15, from Bank of China maintained a Buy rating on Hua Hong Semiconductor Ltd., with a price target…
Citic Securities analyst maintained a Buy rating on Hesai Group Class B on May 28 and set a price target of HK$187.20. The…
